28662 Federal Register / Vol. 83, No. 119 / Wednesday, June 20, 2018 / Notices 

[1]All contract personnel will sign appropriate 

nondisclosure agreements. 

aforementioned public interest factors 

in the context of this investigation. 

If the Commission orders some form 

of remedy, the U.S. Trade 

Representative, as delegated by the 

President, has 60 days to approve or 

disapprove the Commission’s action. 

See Presidential Memorandum of July 

21, 2005, 70 FR 43251 (July 26, 2005). 

During this period, the subject articles 

would be entitled to enter the United 

States under bond, in an amount 

determined by the Commission and 

prescribed by the Secretary of the 

Treasury. The Commission is therefore 

interested in receiving submissions 

concerning the amount of the bond that 

should be imposed if a remedy is 

ordered. 

Written Submissions: The parties to 

the investigation are requested to file 

written submissions on the questions 

identified in this notice. Parties to the 

investigation, interested government 

agencies, and any other interested 

parties are encouraged to file written 

submissions on the issues of remedy, 

the public interest, and bonding. Such 

submissions should address the 

recommended determination by the ALJ 

on remedy and bonding. Complainants 

and OUII are also requested to submit 

proposed remedial orders for the 

Commission’s consideration. 

Complainants are also requested to state 

the date that the asserted patents expire 

and the HTSUS numbers under which 

the accused products are imported. 

Complainants are further requested to 

supply the names of known importers of 

the products at issue in this 

investigation. 

Written submissions and proposed 

remedial orders must be filed no later 

than close of business on June 28, 2018. 

Reply submissions must be filed no later 

than the close of business on July 6, 

2018. Initial written submissions may 

not exceed 50 pages in length, exclusive 

of any exhibits, while reply submissions 

may not exceed 25 pages in length, 

exclusive of any exhibits. No further 

submissions on any of these issues will 

be permitted unless otherwise ordered 

by the Commission. 

Persons filing written submissions 

must file the original document 

electronically on or before the deadlines 

stated above and submit eight (8) true 

paper copies to the Office of the 

Secretary by noon the next day pursuant 

to section 210.4(f) of the Commission’s 

Rules of Practice and Procedure (19 CFR 

210.4(f)). Submissions should refer to 

the investigation number (‘‘Inv. No. 

337–TA–1044’’) in a prominent place on 

the cover page and/or the first page. (See 

Handbook for Electronic Filing 

Procedures, https://www.usitc.gov/ 

secretary/documents/handbook_on_

filing_procedures.pdf). Persons with 

questions regarding filing should 

contact the Secretary (202–205–2000). 

Any person desiring to submit a 

document to the Commission in 

confidence must request confidential 

treatment. All such requests should be 

directed to the Secretary to the 

Commission and must include a full 

statement of the reasons why the 

Commission should grant such 

treatment. See 19 CFR 201.6. Documents 

for which confidential treatment by the 

Commission is properly sought will be 

treated accordingly. All information, 

including confidential business 

information and documents for which 

confidential treatment is properly 

sought, submitted to the Commission for 

purposes of this Investigation may be 

disclosed to and used: (i) By the 

Commission, its employees and Offices, 

and contract personnel (a) for 

developing or maintaining the records 

of this or a related proceeding, or (b) in 

internal investigations, audits, reviews, 

and evaluations relating to the 

programs, personnel, and operations of 

the Commission including under 5 

U.S.C. Appendix 3; or (ii) by U.S. 

government employees and contract 

personnel,[1] solely for cybersecurity 

purposes. All non-confidential written 

submissions will be available for public 

inspection at the Office of the Secretary 

and on EDIS. 

The authority for the Commission’s 

determination is contained in section 

337 of the Tariff Act of 1930, as 

amended (19 U.S.C. 1337), and in part 

210 of the Commission’s Rules of 

Practice and Procedure (19 CFR part 

210). 

By order of the Commission. 

Issued: June 14, 2018. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2018–13191 Filed 6–19–18; 8:45 am] 

BILLING CODE 7020–02–P 

INTERNATIONAL TRADE 

COMMISSION 

[Investigation No. 332–567] 

Generalized System of Preferences: 

Possible Modifications, 2017 Review 

AGENCY: United States International 

Trade Commission. 

ACTION: Notice of amendment of scope 

of investigation. 

SUMMARY: Following receipt on June 6, 

2018 of a correction to the United States 

Trade Representative’s (USTR) request 

letter of May 18, 2018, the U.S. 

International Trade Commission 

(Commission) has amended the scope of 

its investigation No. 332–567, 

Generalized System of Preferences: 

Possible Modifications, 2017 Review, 

and will treat ferroniobium, nesoi, from 

Brazil, provided for in subheading 

7202.93.80 of the Harmonized Tariff 

Schedule, as having been listed in Table 

E of the Annex to the USTR’s request 

letter instead of Table D. As a result, the 

Commission will also provide advice for 

this article with respect to whether a 

like or directly competitive article was 

being produced in the United States in 

any of the preceding three calendar 

years. 

DATES: 

June 4, 2018: Deadline for filing 

requests to appear at the public hearing. 

June 7, 2018: Deadline for filing prehearing briefs and statements. 

June 14, 2018: Public hearing. 

June 21, 2018: Deadline for filing 

post-hearing briefs and statements. 

June 21, 2018: Deadline for filing all 

other written submissions. 

September 7, 2018: Transmittal of 

Commission report to the USTR. 

ADDRESSES: All Commission offices, 

including the Commission’s hearing 

rooms, are located in the United States 

International Trade Commission 

Building, 500 E Street SW, Washington, 

DC. All written submissions should be 

addressed to the Secretary, United 

States International Trade Commission, 

500 E Street SW, Washington, DC 

20436. The public record for this 

investigation may be viewed on the 

Commission’s electronic docket (EDIS) 

at https://edis.usitc.gov. 

FOR FURTHER INFORMATION CONTACT: 

Information specific to this investigation 

may be obtained from Sabina Neumann, 

Project Leader, Office of Industries 

(202–205–3000 or sabina.neumann@

usitc.gov), Mark Brininstool, Deputy 

Project Leader, Office of Industries 

(202–708–1395 or mark.brininstool@

usitc.gov), or Marin Weaver, Technical 

Advisor, Office of Industries (202–205– 

3461 or marin.weaver@usitc.gov. For 

information on the legal aspects of this 

investigation, contact William Gearhart 

of the Commission’s Office of the 

General Counsel (202–205–3091 or 

william.gearhart@usitc.gov). The media 

should contact Margaret O’Laughlin, 

Office of External Relations (202–205– 

1819 or margaret.olaughlin@usitc.gov). 

Hearing-impaired individuals may 

obtain information on this matter by 

contacting the Commission’s TDD 

terminal at 202–205–1810. General 

information concerning the Commission 


sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 83, No. 119 / Wednesday, June 20, 2018 / Notices 28663 

may also be obtained by accessing its 

website (http://www.usitc.gov). Persons 

with mobility impairments who will 

need special assistance in gaining access 

to the Commission should contact the 

Office of the Secretary at 202–205–2000. 

Background: All dates and other 

information relating to this investigation 

remain the same as in the Commission’s 

notice of investigation and public 

hearing issued on May 23, 2018 and 

published in the Federal Register of 

May 25, 2018 (83 FR 24342). 

By order of the Commission. 

Issued: June 14, 2018. 

Lisa Barton, 

Secretary to the Commission. 

[FR Doc. 2018–13176 Filed 6–19–18; 8:45 am] 

BILLING CODE 7020–02–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Importer of Controlled Substances 

Application: Fisher Clinical Services, 

Inc. 

ACTION: Notice of application. 

DATES: Registered bulk manufacturers of 

the affected basic classes, and 

applicants therefore, may file written 

comments on or objections to the 

issuance of the proposed registration on 

or before July 20, 2018. Such persons 

may also file a written request for a 

hearing on the application on or before 

July 20, 2018. 

ADDRESSES: Written comments should 

be sent to: Drug Enforcement 

Administration, Attention: DEA Federal 

Register Representative/DRW, 8701 

Morrissette Drive, Springfield, Virginia 

22152. All requests for hearing must be 

sent to: Drug Enforcement 

Administration, Attn: Administrator, 

8701 Morrissette Drive, Springfield, 

Virginia 22152. All requests for hearing 

should also be sent to: (1) Drug 

Enforcement Administration, Attn: 

Hearing Clerk/LJ, 8701 Morrissette 

Drive, Springfield, Virginia 22152; and 

(2) Drug Enforcement Administration, 

Attn: DEA Federal Register 

Representative/DRW, 8701 Morrissette 

Drive, Springfield, Virginia 22152. 

SUPPLEMENTARY INFORMATION: The 

Attorney General has delegated his 

authority under the Controlled 

Substances Act to the Administrator of 

the Drug Enforcement Administration 

(DEA), 28 CFR 0.100(b). Authority to 

exercise all necessary functions with 

respect to the promulgation and 

implementation of 21 CFR part 1301, 

incident to the registration of 

manufacturers, distributors, dispensers, 

importers, and exporters of controlled 

substances (other than final orders in 

connection with suspension, denial, or 

revocation of registration) has been 

redelegated to the Assistant 

Administrator of the DEA Diversion 

Control Division (‘‘Assistant 

Administrator’’) pursuant to section 7 of 

28 CFR part 0, appendix to subpart R. 

In accordance with 21 CFR 

1301.34(a), this is notice that on March 

16, 2018, Fisher Clinical Services, Inc., 

7554 Schantz Road, Allentown, 

Pennsylvania 18106 applied to be 

registered as an importer of 1-[1-(2- 

Thienyl)cyclohexyl]pyrrolidine (7473), 

a basic class of controlled substance 

listed in schedule I. 

The company plans to import the 

controlled substance in finished dosage 

form for testing and clinical trials 

purposes only. 

Approval of permit applications will 

occur only when the registrant’s 

business activity is consistent with what 

is authorized under to 21 U.S.C. 

952(a)(2). Authorization will not extend 

to the import of FDA approved or nonapproved finished dosage forms for 

commercial sale. 

Dated: June 12, 2018. 

John J. Martin, 

Assistant Administrator. 

[FR Doc. 2018–13224 Filed 6–19–18; 8:45 am] 

BILLING CODE 4410–09–P 

DEPARTMENT OF JUSTICE 

Drug Enforcement Administration 

[Docket No. DEA–392] 

Bulk Manufacturer of Controlled 

Substances Registration 

ACTION: Notice of registration. 

SUMMARY: Registrants listed below have 

applied for and been granted 

registration by the Drug Enforcement 

Administration (DEA) as bulk 

manufacturers of various classes of 

schedule I and II controlled substances. 

SUPPLEMENTARY INFORMATION: The 

companies listed below applied to be 

registered as bulk manufacturers of 

various basic classes of controlled 

substances. Information on previously 

published notices is listed in the table 

below. No comments or objections were 

submitted for these notices. 

Company FR Docket Published 

AMRI Rensselaer, Inc .................................................................................................................................... 83 FR 5808 February 9, 2018. 

Stepan Company ........................................................................................................................................... 83 FR 9029 March 2, 2018. 

Research Triangle Institute ............................................................................................................................ 83 FR 10523 March 9, 2018. 

Rhodes Technologies .................................................................................................................................... 83 FR 12407 March 21, 2018. 

Synthcon, LLC ............................................................................................................................................... 83 FR 13141 March 27, 2018. 

National Center for Natural Products—Research NIDA MPROJECT .......................................................... 83 FR 13522 March 29, 2018. 

Insys Manufacturing LLC ............................................................................................................................... 83 FR 13522 March 29, 2018. 

Navinta LLC ................................................................................................................................................... 83 FR 13521 March 29, 2018. 

The DEA has considered the factors in 

21 U.S.C. 823(a) and determined that 

the registration of these registrants to 

manufacture the applicable basic classes 

of controlled substances is consistent 

with the public interest and with United 

States obligations under international 

treaties, conventions, or protocols in 

effect on May 1, 1971. The DEA 

investigated each of the company’s 

maintenance of effective controls 

against diversion by inspecting and 

testing each company’s physical 

security systems, verifying each 

company’s compliance with state and 

local laws, and reviewing each 

company’s background and history. 

Therefore, pursuant to 21 U.S.C. 

823(a), and in accordance with 21 CFR 

1301.33, the DEA has granted a 

registration as a bulk manufacturer to 

the above listed companies. 

Dated: June 12, 2018. 

John J. Martin, 

Assistant Administrator. 

[FR Doc. 2018–13223 Filed 6–19–18; 8:45 am] 

BILLING CODE 4410–09–P 


sradovich on DSK3GMQ082PROD with NOTICES